Systasy Named a Top 10 Drug Discovery and Development Solution Provider in Europe
May 2, 2019 – Munich
Systasy Bioscience GmbH is selected as one of the “Top 10 Drug Discovery and Development Solution Providers in Europe 2019” by Pharma Tech Outlook magazine.
In its annual listing, the magazine names ten companies that are at the forefront of providing drug discovery and development solutions and impacting the industry. The selection was made by a distinguished panel comprising CEOs, CIOs, VCs, and analysts along with the Pharma Tech Outlook’s editorial board. The panel chose Systasy, stating that all top 10 companies “demonstrate an ability to develop innovative technologies combined with outstanding customer service.”
”We are honored to be named among the top ten solution providers engaged in providing drug discovery and development solutions”, said Dr. Sven Wichert, CEO of Systasy. “This award certifies our capabilities and our dedication to our vision: That is complementing the recent scientific insights in the genetics of brain diseases with a systems-level pharmacological strategy in drug discovery to optimize and boost the development of medication to treat the symptoms of psychiatric and neurodegenerative illnesses.”
Source: Pharma Tech Outlook, Drug Discovery and Development Europe Special, April 2019